Hay, Annette - Queen's University - Department of Medicine

个人简介

Dr. Annette Hay is a Hematologist and clinician scientist within the Department of Medicine, cross appointed to the Departments of Oncology and Pediatrics. Her research focus is in clinical trials. Having completed medical and hematology training in Scotland, Dr. Hay came to Canada where she undertook 2 ½ years of fellowship with the NCIC Clinical Trials Group. She now holds a Senior Investigator position with this group, leading clinical trials for patients with cancer, in collaboration with investigators across Canada and beyond. Dr. Hay’s clinical practice includes all areas of Hematology, with special interest in hematological malignancies. Clinics are held at the Cancer Center of Southeastern Ontario. In 2012 she was awarded the prestigious John H. Crookston Award from the Canadian Hematology Society for research on the treatment of Hodgkin Lymphoma, and in 2014 was the inaugural recipient of the NCIC Clinical Trials Group Dr. Ralph Meyer Phase III Young Investigator Award and in 2015 received the Queen's University Internal Medicine Sub-specialty Teaching Award.

研究领域

Clinical trial design, conduct and analysis: Completion of phase I, II and III trials for patients with lymphoma, myeloma, leukemia and sarcoma. Clinical trial methodology: Investigation of means to conduct trials more efficiently, while maintaining patient safety and privacy. Under-represented populations: Enhancing research opportunities and clinical trial uptake for the elderly, and adolescents and young adults with cancer. Economic analyses: Determining the costs and benefits of an intervention, aiding policy makers.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, Kumar R, Chalchal HI, Salim M, Laister RC, Crocker S, Gibson SB, Toguchi M, Lyons JF, Xu H, Powers J, Sederias J, Seymour L, Hay AE. Leuk Lymphoma. 2016 Oct 17:1-8. [Epub ahead of print] PMID: 27750483 Similar articles Select item 27338095 A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T. Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. No abstract available. PMID: 27338095 Similar articles Select item 27266754 Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12. Baetz T, Chen BE, Couban S, Tom Kouroukis C, Buckstein R, Kuruvilla J, Howson-Jan K, Szwajcer D, Federico M, Meyer RM, Djurfeldt MS, Hay AE, Shepherd L, Crump M. Leuk Lymphoma. 2017 Jan;58(1):64-69. PMID: 27266754 Similar articles Select item 26376958 A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T. Leuk Lymphoma. 2016;57(6):1463-6. doi: 10.3109/10428194.2015.1091927. No abstract available. PMID: 26376958